SLC6A3 and Parkinson disease: Neurodegenerative parkinsonian syndromes including Parkinson’s disease (PD) and the rarer atypical neurodegenerative parkinsonian syndromes such as progressive supranuclear palsy (PSP), parkinsonian variant of multiple system atrophy (MSA-P), and corticobasal degeneration are associated with nigrostriatal degeneration resulting in the loss of dopamine transporters (DAT) in the caudate and putamen nuclei of the (dorsal) striatum secondary to the degeneration of pigmented cells in the substantia nigra pars compacta1,2.